RenovoRx, Inc.
corporate_fare Company Profile
RenovoRx, Inc. (NASDAQ:RNXT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 30 items for RNXT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for RNXT spans 10-Q, 8-K, 10-K/A, DEF 14A.
Recent high-impact activity:
- RenovoRx 10-Q: Q3 Revenue $1.07M, Cash $10.4M, Runway Into 2H 2027
- Q3 Revenue Tops $1M, Up Nearly 300% Year-Over-Year; Guidance Reaffirmed
- RenovoRx Publishes PK/PD Data Showing 51% Tumor-Site Drug Extraction in Pancreatic Cancer Trial
- RenovoRx Q2 2026: Record Revenue, Full Enrollment, and Cash Runway Through 2027
- RenovoRx Reports Record Q2 Revenue, Raises 2026 Guidance to $3.75M-$4.25M
Financial Snapshot
Short Interest & Short Volume
1.64 days to coverFINRA reported short interest of 864,570 shares in RNXT as of the October 15, 2026 settlement, a 8.7% decrease from the prior period — about 1.6 days to cover at its recent average daily volume. On November 5, 2026, 51.5% of RNXT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.